Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported compensation-related equity activity. He exercised 54,000 Restricted Stock Units (RSUs), which converted into an equal number of common shares. In connection with this vesting, 18,711 common shares were withheld by MariMed to cover tax obligations, rather than sold on the open market. Following these transactions, Crandall directly holds 958,140 shares of MariMed common stock, reflecting a routine RSU vesting and associated tax-withholding disposition.
Gildea Edward J reported acquisition or exercise transactions in this Form 4 filing.
MariMed Inc. director Edward J. Gildea reported new equity compensation. On June 4, 2026, he was granted 75,000 Restricted Stock Units (RSUs), each convertible into one share of common stock. The RSUs vest in full one year from the grant date. Following this filing, he directly holds 905,208 shares of common stock and a separate award of 75,000 RSUs.
MariMed Inc. director Allen David R reported a new equity award rather than an open-market trade. On June 4, he received 75,000 Restricted Stock Units (RSUs), which each convert into one share of common stock on a one-for-one basis.
The RSUs will vest in full one year from the grant date under his award agreement. After this filing, he directly holds 476,144 shares of common stock and a separate position of 75,000 RSUs, highlighting a compensation-related grant instead of a buy or sell in the market.
MARIMED INC. director Eva Selhub, M.D. reported a compensation-related equity award. She received 75,000 Restricted Stock Units (RSUs), which are a form of stock-based compensation, at a grant price of $0.00 per unit.
According to the footnotes, these RSUs convert into common stock on a one-for-one basis and will vest in full one year from the grant date, based on the award agreement between the company and Selhub. The filing also shows she directly holds 482,671 shares of common stock following the reported transactions. This Form 4 reflects an equity grant rather than any open-market share purchase or sale.
MariMed Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders re-elected four directors—Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.—to serve until the next annual meeting or until successors are elected and qualified.
Stockholders also approved, on an advisory basis, the appointment of M&K CPAs PLLC as MariMed’s independent auditors for the 2026 fiscal year, with a substantial majority of votes cast in favor.
MariMed Inc. Chief Operating Officer Timothy Shaw reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised RSUs to acquire 40,625 shares of common stock, which convert on a one-for-one basis, and 14,077 shares were withheld by the company to cover tax obligations at a value of $0.0805 per share. After these transactions, Shaw holds 9,398,325 shares of common stock directly. An additional 2,000,000 shares are held by the Shaw Family Trust for the benefit of his children, and he disclaims beneficial ownership of those securities. Following this vesting event, 121,875 RSUs from the November 29, 2024 grant remain outstanding and are scheduled to vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027, subject to the award agreement.
MARIMED INC. President and CEO Jon R. Levine reported equity compensation activity involving company common stock and restricted stock units. He exercised 46,875 RSUs into an equal number of common shares, and 16,243 shares were withheld by the company to cover tax obligations related to this vesting.
Following these transactions, Levine directly held 21,354,861 shares of common stock. An additional 6,684,640 shares are held by the Jon Levine Family Trust for the benefit of his spouse and children, for which he disclaims beneficial ownership. After this vesting, 140,625 RSUs from the November 29, 2024 grant remain outstanding, scheduled to vest in three equal installments on November 29, 2026, May 29, 2027 and November 29, 2027.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported routine equity compensation activity involving restricted stock units. On May 29, 2026, RSUs converted into 37,500 shares of common stock on a one-for-one basis, increasing his direct holdings to 917,134 shares.
To cover tax obligations from this vesting, 12,994 shares of common stock were withheld by the company at a price of $0.0805 per share. Following the transaction, Crandall also held 112,500 unvested RSUs that are scheduled to vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027, under an existing award agreement.
MariMed Inc. President and CEO Jon R. Levine reported open-market purchases of 60,000 shares of common stock on May 22, 2026. The buys were executed at prices of $0.0745, $0.0750, and $0.0767 per share. Following these purchases, he directly owns 21,307,986 common shares.
An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children. Levine disclaims beneficial ownership of the trust-held shares, meaning they are attributed to the trust rather than to him personally.
MariMed Inc. President and CEO Jon R. Levine reported an open-market purchase of 40,000 shares of common stock at $0.075 per share. Following this trade, he owns 21,247,986 shares directly. A separate 6,684,640 shares are held by the Jon Levine Family Trust for his spouse and children, which he disclaims as beneficially owned.